Expression Profile of Peripheral Immune Cells-derived Coding and Long Non-coding RNAs in Patients With Proliferative Vitreoretinopathy

Yao Ni  
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center of Sun Yat-sen University

Fangyuan Liu  
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center of Sun Yat-sen University

Xiao Hu  
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center of Sun Yat-sen University

Yingyan Qin  
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center of Sun Yat-sen University

Zhaotian Zhang (zhangzhaotian@gzzoc.com)  
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University Add: 54S Xianlie Road, Guangzhou, 510060, China  
https://orcid.org/0000-0003-0436-3338

Research article

Keywords: proliferative vitreoretinopathy, gene expression profile, long non-coding RNAs, immune-related pathway

DOI: https://doi.org/10.21203/rs.3.rs-74786/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction: Peripheral immune response has been revealed to play a critical role in proliferative vitreoretinopathy (PVR). However, the reliable immune-related factors that are acting as prognostic indicators or therapeutic targets for PVR remain to explore further.

Methods: In the current study, we applied whole-transcriptome sequencing to profile peripheral blood mononuclear cells (PBMCs) from PVR patients and also analyzed IncRNA-mRNA interactions in peripheral immune cells to explore the pathways that might mediate immunopathology and resultant retinal damage in PVR. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses and Ingenuity Pathway Analysis (IPA) were employed to classify the function of these differentially expressed genes (DEGs).

Results: Compared to the controls, there were 319 genes upregulated, and 191 genes downregulated in PVR patients. GO, and KEGG enrichment analyses as well as IPA showed that these upregulated genes were significantly enriched in immune-related and infection-relate terms. Immune-related gene NFKBIA, CXCL2, and CXCL8 were detected as hub-genes in the co-expression network, while IncRNAs such as AC007032.1, AC037198.2, AL929472.2, and SLED1 were highly co-expressed with them. IncRNA-mRNA interactions analysis also showed that putative targeted genes of these differentially expressed IncRNAs were also significantly enriched in immune-related or infection-relate pathways.

Conclusion: Our study highlights the transformation of immune-related genes/pathways in PVR by comparing controls, and validates several critical genes and IncRNAs, which are serving as potential diagnostic markers for PVR patients.

Introduction

Proliferative vitreoretinopathy (PVR) is a critically blinding complication that occurs during rhegmatogenous retinal detachment (RRD), before or after surgery. It is caused by the proliferation of glial cells or RPE cells to form a fibrous membrane at the neural retinal surface or even in the retina. Immune cells involved in the pathogenesis of PVR, such as monocyte/macrophage infiltration and activity contributed to the progress of PVR. And, some inflammatory-related genes are identified that can predict the susceptibility of PVR in populations. Recently, the interaction of long non-coding RNAs (lncRNAs) and protein-coding RNAs (mRNAs) has been revealed playing a significant role in diseases related to inflammation and immunity. However, despite some IncRNAs, such as MALAT1 that had been unveiled by some publications, there are no reliable IncRNAs currently implicating in clinical practice acting as prognostic indicators or therapeutic targets for PVR patients. Thus, subsequent studies to identify more critical IncRNAs associated with PVR are warranted.

In the present study, we hypothesized that transcriptomes of peripheral immune cells in PVR might be altered, which are the potential cause for the initiation or progression of PVR. Peripheral blood samples were taken from patients undergoing standard three-port pars plana vitrectomy for indications of PVR secondary to RRD and the entire transcriptome sequencing was performed. Patients with idiopathic epiretinal membrane (ERM) underwent pars plana vitrectomy were used as controls. Patients were excluded from analysis if they were with systemic diseases (e.g., diabetes, immunological diseases, infections, etc.) that could influence systemic inflammation. With the sequencing data, we applied Gene Ontology (GO) analysis, Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis and Ingenuity Pathway Analysis (IPA), as well as gene-IncRNA co-expression analysis to see the differences in transcriptome level between PVR patients and controls. We also validated some selected differentially expressed IncRNAs by quantitative real-time polymerase chain reaction (qPCR) assay. The results of the current study provide novel insights into PVR pathogenesis and treatment therapeutic targets.

Methods And Design

Ethics statement and clinical sample collection

This study was approved by the ethics committees of the Zhongshan Ophthalmic Center. The peripheral blood samples were taken in accordance with the Declaration of Helsinki and written consent was obtained from all participants. Patients diagnosed as primary rhegmatogenous retinal detachment (RRD) with serious PVR (≥ Grade C), were included in this study. Patients diagnosed as idiopathic epiretinal membrane (ERM) and scheduled to have PPV during the same period were included as negative controls (ERM group). The blood samples were collected from patients before surgery.

RNA extraction and cDNA library construction

Using Ficoll-Paque™ PREMIUM Media (GE Healthcare Life Sciences, Massachusetts, America) and SepMate™-50 (STEMCELL Technologies, Vancouver, Canada), approximately 5 mL of anticoagulated peripheral blood was centrifuged at 500 g for 30 min, and the thin white layer was collected as PBMC. RNeasy Mini Kit (Qiagen Corporation, Hilden, Germany) was used to extract the total RNA from PBMC. After using Agilent 4200 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) to determine the RNA integrity number and quantity, the rRNA was removed by Epicentre Ribo-zero rRNA Removal Kit (Epicentre, Madison, WI, USA). Subsequently, the DNA was cleaned by DNase and then captured and purified by magnet beads (Vazyme, Nanjing, China). The purified RNA was interrupted into short fragments by adding fragmentation buffer, then the first-strand cDNA was synthesized and double-strand cDNA was obtained thereafter with VAHTS Universal V6 RNA-seq Library Prep Kit for Illumina (Vazyme, Nanjing, China).
Adapters were then connected to the cDNAs and Agilent 4200 Bioanalyzer, as well as qPCR, were used to verify the fragment size and amplify the templates. The constructed library was then loaded on the Illumina HiSeq X Ten system for sequencing.

Sequence analysis and functional annotation

We used FastQC first to check the quality of raw reads and then processed with Cutadapt software to generate clean reads by trim adaptor sequences and removed the low-quality sequences.11 HiSAT2 was used to align the clean reads to the hg19 human reference genome.12 Mapped reads used the featureCount software to obtain gene expression profiles,13–15 and then the differential expression analysis was executed via the DESeq2 package on R programmer.16 |Fold change| > 1.5 and P-value < .05 were decided upon as the significance of differentially expressed genes. GO and KEGG enrichment analyses were then performed using the Clusterprofiler R package.17 For further functional analysis, differentially expressed transcriptome between PVR and iERM patients, including gene symbols and expression values were uploaded into IPA software (Qiagen, Germany). The canonical pathways, diseases and biofunctions as well as gene networks analysis were processed.

QPCR validation

Total RNA was isolated as mentioned above, and the cDNA was then synthesized with HiScript II Q Select RT SuperMix for qPCR (Vazyme, Nanjing, China). Roche lightcycler 96 was then used to perform qPCR. Beta-actin was used as the internal control. The melting curve was used to confirm reaction specificity and relative expression was calculated by the 2^−ΔΔCt method. Primer sequences and product length were listed in Table 1.

| Gene            | Primer Sequence (5'−3') | Product length |
|-----------------|------------------------|----------------|
| AC037198.1     | F: CCTCATACTCGGCATTCTT | 139 bp         |
|                | R: GCCTTCCCACTGATGCT   |                |
| ZNF433-AS1     | F: CCGGAATATCTGGAGCTGA | 111 bp         |
|                | R: GTCTCAATGGCAACCAGTT |                |
| Beta-actin     | F: CTCTTCCAGCCTTTCTCTCT | 116 bp         |
|                | R: AGCAGTGTGTGCGCAGAG  |                |

Statistical analyses

GraphPad Prism 7.0 (GraphPad company, San Diego, USA) was used to compare the lncRNA expression differences obtained by qPCR assay referring to the Mann-Whitney U test between PVR and iERM groups. A P-value ≤ .05 was considered statistically significant.

Results

Characteristics of the subjects

There were six males and six females in the PVR group, and eight males and five females in the iERM group. The average age of the PVR group was 53.3 ± 10.6 years old, and that of the iERM group was 60.0 ± 9.7 years old. The differences in age and gender between PVR and iERM groups were not statistically different (P>.05).

Identification of differentially expressed transcriptome

Using 1.5-fold expression difference as a cutoff, 510 genes were found differentially expressed between PVR patients and iERM patients, among which 319 were upregulated and 191 were downregulated (Fig. 1A). As expected, these two kinds of patients could be clustered into separated groups using the differentially expressed genes (DEGs) (Fig. 1B), highlighting the apparent transcriptomic difference between PVR and iERM. Differentially expressed transcripts between PVR and iERM was also analyzed in this study.

Besides, for the 5,138 differentially expressed transcripts (DETs) (Figure S1; supplementary file), 64.38% of them were protein-coding RNAs, whereas 19.26% were lncRNAs (Figure S2A; supplementary file). The length of lncRNA varies from 1,000 to larger than 10,000 (Figure S2B; supplementary file). We also performed an unsupervised cluster analysis with the DETs. Similar to the gene clustering analysis, samples were significantly separated in accordance with two patient groups.

Gene Ontology analysis and KEGG analysis

To explore the biology underlying the deferentially expressed gene further, we performed an overrepresentation analysis of GO terms and KEGG pathways using the R program with the ClusterProfiler package. It is very interesting to note that most of the upregulated genes were enriched in immune system-related terms, including immunoglobulin, complement, and immune response (Fig. 2A); while the downregulated GO terms were irrelevant to the immune system (Figure S3A; supplementary file).
Upregulated genes of PVR patients compared with iERM patients were enriched in many pathways from KEGG (Fig. 2B). To our surprise, many infectious pathways, including malaria, legionellosis, and Chagas disease, were involved with high significance. Besides, pathways affecting the immune system, including IL-17 signaling, TNF signaling, as well as rheumatoid arthritis, were enriched. Much different from the upregulated genes, the downregulated genes were poorly enriched in KEGG pathway enrichment (Figure S3B; supplementary file).

**Enriched Pathway, diseases, biofunctions and interaction network by IPA analysis**

We used IPA to analysis the significant changed 752 transcriptomes (P < 0.05 and fold-change > 1.5) between patient PVR and iERM patients. With IPA, we revealed these changed genes are closely related to 26 canonical pathways. The most significant of those are shown in Table 2. 5 out of top ten pathways are related to innate and adaptive immune cells especially Th17 cells and its cytokines IL-17A and IL-17F. With IPA, we also found similar change as we revealed in GO and KEGG analysis: Pathways related to immune reaction were also enriched. For the top four scored networks (Table S1, supplementary file), 2 of them were immune function related. These two networks are shown in Fig. 3: Cell-To-Cell Signaling and Interaction, Cellular Movement, Immune Cell Trafficking (score 23, Fig. 3A); and Gastrointestinal Disease, Inflammatory Disease, Inflammatory Response (score 21, Fig. 3B).

| Ingenuity Canonical Pathways                                      | -log(p-value) | Ratio | Molecules                    |
|------------------------------------------------------------------|---------------|-------|------------------------------|
| Communication between Innate and Adaptive Immune Cells           | 3.53          | 0.0625| CCL3,CXCL8,IGHA1,IGHE,IGHG2,IL1B |
| Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F | 3.22          | 0.167 | CCL3,CXCL1,IL1B             |
| Differential Regulation of Cytokine Production in Intestinal Epithelial Cells by IL-17A and IL-17F | 2.9           | 0.13  | CCL3,CXCL1,IL1B             |
| Role of IL-17A in Arthritis                                     | 2.75          | 0.0727| CXCL1,CXCL2,CXCL8,NFKBIA     |
| Airway Pathology in Chronic Obstructive Pulmonary Disease        | 2.63          | 0.25  | CXCL2,CXCL8                 |
| Glutathione-mediated Detoxification                              | 2.48          | 0.0938| GSTM1,GSTM4,HPGDS           |
| TREM1 Signaling                                                  | 2.26          | 0.0533| CCL3,CXCL2,CXCL8,IL1B       |
| Role of IL-17A in Psoriasis                                     | 2.2           | 0.154 | CXCL1,CXCL8                 |
| Atherosclerosis Signaling                                        | 2.17          | 0.0397| COL1A1,CXCL8,IL1B,PLAAT2,TPSAB1/TPSB2 |
| Role of IL-17F in Allergic Inflammatory Airway Diseases         | 2.15          | 0.0714| CXCL1,CXCL8,IL1B            |

**mRNA and IncRNA co-expression analysis**

As lncRNAs are also important participants in disease process. Based on the correlation of the significantly regulated protein-coding mRNA with IncRNA, we constructed co-expression networks to analyze their interaction and to find out the potential therapeutic target. Pearson correlation coefficient was calculated for each pair and significantly correlated RNA pairs were chosen (r > 0.8, P < .05 as the threshold). As shown in Fig. 4, immune-related gene NFKBIA, and chemokines CXCL2 and CXCL8 were of high hubness in the co-expression network, highlighting their important biological role in the difference between PVR and iERM. Besides, we found several lncRNAs were highly co-expressed with these genes, including AC007032.1, AC037198.2, AL929472.2, SLED1, etc., indicating the key regulation values of them.

We searched further to look for the lncRNA-mRNA interactions, inspecting the chromosome location of regulated lncRNAs to see if they had up- or down-stream 10 kb or overlapping mRNAs. As a result, 630 lncRNAs that had nearby DEGs were found, including 290 upregulated and 340 downregulated lncRNAs. GO, and KEGG analyses and also IPA were conducted as above (Fig. 5 and Table 3). Like that of DETs GO analysis, the upregulated IncRNAs had more enriched GO terms compared to the downregulated IncRNAs though few of which was immune related (Fig. 5A and Figure S4A). For the KEGG analysis, fewer pathways were enriched(Figure 5B and Figure S4B). results above might due to many functions of IncRNA that are still unclear. However, in IPA analysis, though none of the top ten enriched pathways were immune related pathways, we found Virus Entry via Endocytic Pathways were enriched. Further, the top 2 scored networks are relate to Ophthalmic Disease or Immunological Disease respectively (Table S2; supplementary file).
Table 3
Top significantly enriched canonical pathways of LncRNAs in PVR patients

| Ingenuity Canonical Pathways                          | -log(p-value) | Ratio | Molecules                                                                 |
|------------------------------------------------------|---------------|-------|---------------------------------------------------------------------------|
| D-myo-inositol-5-phosphate Metabolism                | 2.85          | 0.0641| DOT1L, INPP5B, MDP1, NUDT5, PLCG1, PPIP5K1, PPP2R5A, PTPN6, PTPRM, SET    |
| Superpathway of Inositol Phosphate Compounds         | 2.12          | 0.0505| DOT1L, INPP5B, MDP1, NUDT5, PLCG1, PPIP5K1, PPP2R5A, PTPN6, PTPRM, SET    |
| Endocannabinoid Cancer Inhibition Pathway            | 2.04          | 0.0559| ATF3, CREB1, GNB1L, LEF1, MAP2K4, PRKACA, SPTLC1, TCF4                    |
| Heme Biosynthesis II                                 | 1.87          | 0.222 | HMBS, UROD                                                                |
| Folate Transformations I                             | 1.87          | 0.222 | MTHFD2, MTHFR                                                             |
| Salvage Pathways of Pyrimidine Ribonucleotides       | 1.84          | 0.0619| CSNK1D, GRK4, MAP2K4, MAPK6, PRKCH, UCKL1                                 |
| Protein Kinase A Signaling                           | 1.76          | 0.0377| ADD1, ADD3, APEX1, CHP1, CREB1, FLNA, GNB1L, LEF1, PLCG1, PRKACA, PRKCH, PTPN4, PTPN6, PTPRM, TCF4 |
| Amyloid Processing                                   | 1.73          | 0.08  | CAPN2, CSNK1D, PRKACA, PSEN2                                             |
| Androgen Signaling                                   | 1.66          | 0.0515| GNA12, GNB1L, KAT7, NCOA1, POLR2J2, POLR2J3, PRKACA, PRKCH                |
| Virus Entry via Endocytic Pathways                   | 1.65          | 0.0561| AP2A1, FLNA, ITGAL, ITGB1, PLCG1, PRKCH                                   |

Validation of differentially expressed IncRNAs

We used qPCR assay to validate the deferentially expressed IncRNAs, while AC037198.2, and ZNF433-AS1 were selected based on differential expression and co-expression analyses. As shown in Fig. 6, these IncRNAs were significantly different among PVR and iERM patients.

Discussion

PVR is still the leading cause of vitreoretinal surgery failure, mainly through retina re-detachment and even intraretinal fibrosis. The incidence of PVR is estimated to be 5–10%. However, as the mechanisms of PVR are still not very clear, it is difficult to predict or treat the condition despite the many efforts that are still being made. In the present study, our results identified differentially expressed mRNA and IncRNA in PBMCs of PVR patients and revealed that gene expression profile and molecular signature of PVR patients.

The proliferation of cells, mainly RPE and glial cells, is the essential point of PVR development. Clinicians have tried for more than four decades to inhibit the proliferation of cells in the vitreous to prevent PVR but have not had impressive progress. This situation has raised the question of whether there is anything abnormal out of the eye in this disease. The answer to this might come from the immune system.

In the review by Pastor et al., the authors proposed that ischemia, blood-retina barrier breakdown, and inflammation lead to the final PVR based on the collaborative genetic study named “Retina 4 Project”, which found 30 inflammatory-related genes were responsible for PVR. Further, a single nucleotide polymorphism (SNP) analysis in peripheral blood from PVR patients shown that TNF locus which encompasses the gene of TNFα contributes to the development of PVR. It is suggested that PVR might not only be a “local inflammatory condition”, but also could be affected by system regulation.

Compare with these studies, with RNA from peripheral blood mononuclear cells and with GO, KEGG and IPA analysis, we revealed that the immune related pathways or components are closely related to PVR change. We found immunoglobulin and its receptors as well as antigen binding were all up regulated in PBMC from PVR patient. Further, RNAs related to biological process of adaptive immune response and lymphocytes activation were also up regulated indicating microbial infection might play a role in the disease process. In IPA analysis, we found in enriched canonical pathways,
CCL1, CCL3, CXCL8 and especially Th17 cells and its related cytokines IL-17A and IL-17F were emphasized. In previous publication, Th17 and its cytokines are inflammatory mediator to RPE cells, and RPE cells in inflammatory condition were thought to be a key point to PVR formation.

Infection had long been considered as a trigger to immune disease. In the KEGG analysis, to our surprise, rather than immune pathways, infectious related pathways related to amoebiasis, malaria or chagas disease were enriched. As in uveitis, Forrester et al. agreed that infection may directly or indirectly related to noninfectious uveitis in the eye. In this consideration, remind us that infection might be a potential cause of PVR.

LncRNAs are widely expressed in monocytes, macrophages, neutrophils and implicated in the process of inflammation and immunity. Various molecular functions have been ascribed to lncRNAs, including gene regulation in cis, regulation of mRNA stability, and modulation of protein function. In PVR patients, Zhou et al. not only demonstrated that the expression of MALAT1 was significantly upregulated in the proliferating membrane, also found MALAT1 was significantly up-regulated in the peripheral blood. MALAT1 can inhibit the DNA binding activity of NF-κB, reduce the production of inflammatory cytokines, and down-regulate the autoimmune inflammatory response. The knockdown of MALAT1 can increase lipopolysaccharide (LPS)-induced expression of TNFα and IL-6. However, to our surprise, we did not find MALAT1 were upregulated in PBMC in PVR patient.

In our research, by analysis the mRNA and lncRNA co-expression in PBMC, we found immune-related gene NFKBIA, and chemokines CXCL2 and CXCL8 and their associate LncRNA AC007032.1, AC037198.2, AL929472.2, SLED1 were highly associated with PVR. AC007032.1 is associated with immunomodulatory cytokine Nampt, while SLED1 was found up regulated in peripheral blood cells of systemic lupus erythematosus patients. Additionally, within IPA analysis, virus infection relate pathways and immune relate networks were highlighted in PVR patients.

Further, the most obvious changed LncRNA AC037198.2 and ZNF433-AS1 were selected to verify and were proved their actual change in PBMC from PVR patients. LncRNA AC037198.2 is associate with THBS1 (thrombospondin 1) gene, which encoded a secreted protein to mediate cell-to-cell and cell-to-matrix interactions. As for ZNF433-AS1, this LncRNA can suppress ZNF433, which belongs to transcriptional factors with the zinc finger motif, and was found that play an important role in multiple sclerosis, which is an autoimmune disease.

Conclusions

In summary, we provide a landscape of differential expression profile of mRNAs and lncRNAs between PVR and controls and construct an mRNA-lncRNA co-expression network based on the DETs. Pathway enrichment analyses offer novel insights into the pathogenesis of PVR, indicating that PVR might be related with abnormal immune system or previous infection. More importantly, some deferentially expressed lncRNAs, like LncRNA-AC037198.2 and ZNF433-AS1 were appeared in our study, which might be potential molecular signatures for PVR. These results will provide hence our understanding of this disease and provide novel therapeutic targets for PVR patients.

Declarations

ACKNOWLEDGEMENTS

Funding: This study was supported by the Fundamental Research Funds for the Central Universities (20ykpy147) and Natural Science Foundation of Guangdong Province of China (2019A1515010189).

Authorship: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.

Disclosures: Yao Ni, Fangyuan Liu, Xiao Hu, Yingyan Qin and Zhaotian Zhang declare that they have no conflict of interest.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Data Availability: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

References

1. Pennock S, Haddock LJ, Eliott D, Mukai S, Kazlauskas A. Is neutralizing vitreal growth factors a viable strategy to prevent proliferative vitreoretinopathy? Prog Retin Eye Res. 2014;40:16–34.
2. Wang X, Miller EB, Goswami M, et al. Rapid monocyte infiltration following retinal detachment is dependent on non-canonical IL6 signaling through gp130. J Neuroinflammation. 2017;14:121.
3. Pastor JC, Rojas J, Pastor-Idoate S, Di Lauro S, Gonzalez-Buendia L, Delgado-Tirado S. Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences. Prog Retin Eye Res. 2016;51:125–55.
4. Chen J, Ao L, Yang J. Long non-coding RNAs in diseases related to inflammation and immunity. Ann Transl Med. 2019;7:494.
5. Carpenter S, Fitzgerald KA. Cytokines and Long Noncoding RNAs. Cold Spring Harb Perspect Biol 2018;10.
6. Zhou RM, Wang XQ, Yao J, et al. Identification and characterization of proliferative retinopathy-related long noncoding RNAs. Biochem Biophys Res Commun. 2015;465:324–30.
7. Yang S, Yao H, Li M, Li H, Wang F. Long Non-Coding RNA MALAT1 Mediates Transforming Growth Factor Beta1-Induced Epithelial-Mesenchymal Transition of Retinal Pigment Epithelial Cells. Plos One. 2016;11:e0152687.
8. Zandi S, Tappeiner C, Pfister IB, Despont A, Rieben R, Garweg JG. Vitreal Cytokine Profile Differences Between Eyes With Epiretinal Membranes or Macular Holes. Invest Ophthalmol Vis Sci. 2016;57:6320–6.
9. Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637–43.
10. The classification of retinal detachment with proliferative vitreoretinopathy. Ophthalmology. 1983;90:121–5.
11. Kechin A, Boyarskikh U, Kel A, Filipenko M. cutPrimers.: A New Tool for Accurate Cutting of Primers from Reads of Targeted Next Generation Sequencing. J Comput Biol. 2017;24:1138–43.
12. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357–60.
13. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014;30:923–30.
14. Liao Y, Smyth GK, Shi W. The R package Rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47.
15. Liao Y, Smyth GK, Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 2013;41:e108.
16. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
17. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. Omics. 2012;16:284–7.
18. Idrées S, Sridhar J, Kuriyan AE. Proliferative Vitreoretinopathy: A Review. Int Ophthalmol Clin. 2019;59:221–40.
19. Banerjee S, Savant V, Scott RA, Curnow SJ, Wallace GR, Murray PI. Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci. 2007;48:2203–7.
20. Chen Y, Yang P, Li F, Kijlstra A. The effects of Th17 cytokines on the inflammatory mediator production and barrier function of ARPE-19 cells. Plos One. 2011;6:e18139.
21. Forrester JV, Kuffova L, Dick AD. Autoimmunity, Autoinflammation, and Infection in Uveitis. Am J Ophthalmol. 2018;189:77–85.
22. Zhao G, Su Z, Song D, Mao Y, Mao X. The long noncoding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-kappaB. Febs Lett. 2016;590:2884–95.
23. Garten A, Petzold S, Korner A, Imai S, Kiess W. Nampt: linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 2009;20:130–8.
24. Ishii T, Onda H, Tanigawa A, et al. Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients. Dna Res. 2005;12:429–39.
25. Nischwitz S, Cepok S, Kroner A, et al. Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol. 2010;227:162–6.
Figure 1

Differential gene expression. (A) Volcano plot assessment of gene expression between iERM and PVR patients (blue dots indicate downregulated transcriptome and red dots indicate upregulated transcriptome), and (B) Heatmap showing unsupervised cluster analysis of differentially expressed gene between iERM (Blue) and PVR (Red) patients. iERM, idiopathic epiretinal membrane; PVR, proliferative vitreoretinopathy.

Figure 2

Pathway analysis of upregulated genes between iERM and PVR patients. (A) GO analysis data and (B) KEGG analysis data. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 3

Ingenuity Pathway Analysis (IPA)-identified immune related gene networks with score >20. A. Cell-To-Cell Signaling and Interaction, Cellular Movement, Immune Cell Trafficking; B. Gastrointestinal Disease, Inflammatory Disease, Inflammatory Response.
**Figure 4**

Co-expression network of gene-lncRNA network. Red dots indicate upregulated gene/lncRNA and blue dots indicate downregulated gene/lncRNA; solid line represents positive relation, and the dotted line represents negative relation.

**Figure 5**

Pathway analysis of upregulated lncRNAs between iERM and PVR patients. (A) GO analysis data and (B) KEGG analysis data. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.
Figure 6

Validation of two selected lncRNAs. The expression level was normalized to the housekeeping gene beta-actin (*P < .05).

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- TableS1.docx
- TableS2.docx
- Supplementaryfileandthecorrespondingfigurelegends.docx